查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1870952

血液腫瘤藥物市場按治療類別、適應症、給藥途徑、通路和最終用戶分類－2025-2032年全球預測

Blood Cancer Drugs Market by Therapeutic Class, Indication, Route Of Administration, Distribution Channel, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血液癌症治療市場將成長至 1,029.5 億美元，複合年成長率為 10.59%。

關鍵市場統計數據
基準年 2024 459.8億美元
預計年份：2025年 509.6億美元
預測年份 2032 1029.5億美元
複合年成長率 (%) 10.59%

本文從戰略角度概述了科學進步、不斷變化的法規環境以及商業性需求如何影響血液腫瘤治療領域的治療路徑和相關人員的優先事項。

血液腫瘤治療領域正經歷快速的科學進步和策略調整，這正在重塑治療路徑、醫療服務模式和商業性策略。標靶治療、免疫療法和移植技術的進步，以及分子診斷和數位化工具的改進，正在推動更個人化的治療流程的發展。同時，支付方和醫療服務提供者也不斷改進其價值評估和報銷方式，日益重視真實世界數據和以病人為中心的治療結果在商業規劃中的作用。

臨床創新、診斷進步和商業性前景正在匯聚，重新定義血液腫瘤學的治療方法和治療模式。

血液腫瘤的治療模式正沿著多個互補的方向轉變，治療模式也隨之改變。在臨床上，細胞療法和雙特異性療法的成熟拓展了治療選擇，使其超越了傳統的細胞毒性療法，使既往難治性患者群體也能獲得深度且持久的療效。同時，精準靶向的小分子藥物和抗體藥物複合體（ADC）透過提高治療效果指標和提供口服維持治療策略，正在改變疾病的長期管理。

2025年美國關稅調整對血液腫瘤藥物供應鏈韌性籌資策略與商業規劃的影響

美國近期調整的關稅政策將於2025年生效，這增加了製造商、合約合作夥伴和醫療保健採購商跨境採購零件、試劑和成品生技藥品的複雜性。某些原料和特殊零件關稅的提高，以及海關摩擦的加劇，增加了部分供應鏈的准入成本，促使製造商重新評估其籌資策略，並加快對地域分佈廣泛的替代供應商進行資格認證。

針對治療領域、適應症、給藥途徑、分銷管道和最終用戶環境的詳細細分觀點指南戰術性優先排序。

細分市場分析揭示了不同治療領域、適應症、給藥途徑、通路和終端用戶之間的細微差別，這些差異對於優先分配研發和商業資源至關重要。按治療領域分類，我們的目標領域包括化療、免疫療法、幹細胞移植和分子標靶治療，每個領域都有其獨特的臨床價值提案和營運需求。雖然化療仍然是某些適應症的基石療法，但它正面臨著來自免疫療法和分子標靶藥物日益激烈的競爭，這些療法在某些患者群體中具有更好的耐受性和持久緩解效果。我們以適應症為基礎的產品組合涵蓋白血病、淋巴瘤、多發性骨髓瘤和骨髓發育不良症候群。白血病進一步分為急性淋巴性白血病、急性骨髓性白血病、慢性淋巴性白血病和慢性骨髓性白血病。淋巴瘤進一步分為何傑金氏淋巴瘤和非何傑金氏淋巴瘤。同時，多發性骨髓瘤的治療方案被分為第一線、第二線、三線及後續治療。這些更細緻的適應症將決定臨床試驗設計、監管終點和治療順序策略，而特定的亞型則為標靶治療和細胞治療介入提供了更明確的途徑。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 擴大下一代CAR-T細胞療法在難治性血液腫瘤患者的應用，以對抗復發
  • 增加對雙特異性抗體平台的投資，用於白血病中的標靶雙抗原結合。
  • 透過將微小殘留病灶監測與數位生物標記結合，實現個人化治療方法
  • 口服BTK抑制劑的進步提高了患者的依從性，並減少了對輸液中心的依賴。
  • 利Rituximab生物相似藥的出現將促進成本競爭，並擴大治療的可近性。
  • 表觀遺傳調變器標靶組蛋白甲基轉移酵素治療多發性骨髓瘤的臨床評價
  • 新型連接子在提高淋巴瘤選擇性方面的抗體藥物複合體開發平臺取得進展

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按治療類別分類的血液癌症藥物市場

  • 化療
  • 免疫療法
  • 幹細胞移植
  • 標靶治療

第9章 血液腫瘤藥物市場（依適應症分類）

  • 白血病
    • 急性淋巴性白血病
    • 急性骨髓性白血病
    • 慢性淋巴性白血病
    • 慢性骨髓性白血病
  • 淋巴瘤
    • 何傑金氏淋巴瘤
    • 非何傑金氏淋巴瘤
  • 多發性骨髓瘤
    • 一線治療
    • 二級治療
    • 第三線及以後
  • 骨髓發育不良症候群

第10章 血液腫瘤藥物市場（依給藥途徑分類）

  • 靜脈注射
  • 口服
  • 皮下注射

第11章 血液腫瘤藥物市場（依通路分類）

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第12章 血液腫瘤藥物市場（依最終用戶分類）

  • 診所
  • 居家醫療
  • 醫院

第13章：血液腫瘤藥物市場區域概覽

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 血液腫瘤藥物市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國血液腫瘤藥物市場概況

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
    • Roche Holding AG
    • Johnson & Johnson
    • Takeda Pharmaceutical Company Limited
    • Amgen Inc.
    • Novartis AG
    • AstraZeneca plc
    • Gilead Sciences, Inc.
    • Sanofi SA
Product Code: MRR-1A1A064C04E8

The Blood Cancer Drugs Market is projected to grow by USD 102.95 billion at a CAGR of 10.59% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 45.98 billion
Estimated Year [2025] USD 50.96 billion
Forecast Year [2032] USD 102.95 billion
CAGR (%) 10.59%

A strategic overview of scientific momentum regulatory shifts and commercial imperatives shaping treatment pathways and stakeholder priorities across blood cancer therapeutics

The blood cancer therapeutics landscape is undergoing a period of rapid scientific progress and strategic recalibration that is reshaping treatment pathways, care delivery models, and commercial approaches. Advances in targeted agents, immune-based therapies, and transplant technologies are intersecting with improved molecular diagnostics and digital tools to create more personalized treatment algorithms. Concurrently, payers and providers are evolving their approaches to value assessment and reimbursement, elevating the importance of real-world evidence and patient-centered outcomes in commercial planning.

This introduction sets the stage for an evidence-driven executive summary that synthesizes the most consequential developments shaping drug development, regulatory interactions, manufacturing, and access for hematologic malignancies. The intent is to provide a clear, business-focused orientation that equips decision-makers with the contextual understanding necessary to assess investment priorities, alliance opportunities, and operational adjustments. By framing scientific momentum alongside commercial and policy forces, stakeholders can better align R&D, supply chain resilience, and market access strategies to deliver durable patient benefit while managing financial and regulatory risk.

Converging clinical innovations diagnostic advances and commercial expectations that are collectively redefining therapeutic approaches and access models in hematologic oncology

The landscape for blood cancer therapeutics is shifting along multiple, mutually reinforcing axes that together are transforming care paradigms. Clinically, the maturation of cellular therapies and bispecific modalities is expanding treatment options beyond traditional cytotoxic approaches, enabling deep and durable responses in previously refractory populations. At the same time, precision-targeted small molecules and antibody-drug conjugates are refining therapeutic indices and offering oral maintenance strategies that change long-term disease management.

On the diagnostic and digital front, broader adoption of next-generation sequencing and minimal residual disease assays is enabling earlier intervention and more adaptive treatment sequencing. These diagnostic capabilities are creating opportunities for companion diagnostics and for trial designs that accelerate regulatory interactions. Commercially, payers are increasingly demanding robust real-world evidence and outcome-based contracting, which is redirecting investments toward post-approval evidence generation and patient support mechanisms. Manufacturing advances in cell therapy and biologics scale-up, alongside advances in cold-chain logistics and contract manufacturing capacity, are reducing some barriers to broader adoption while introducing new operational complexities. Taken together, these shifts are producing a more nuanced, multidisciplinary ecosystem where clinical efficacy, manufacturability, evidence generation, and commercial access must be considered in parallel to succeed.

How recent United States tariff adjustments have reshaped supply chain resilience sourcing strategies and commercial planning for blood cancer therapeutics in 2025

Recent tariff adjustments enacted in the United States during 2025 have introduced a layer of complexity for manufacturers, contract partners, and healthcare purchasers that source components, reagents, and finished biologics across borders. Increased duties and customs friction on certain raw materials and specialized components have elevated the cost of entry for some supply chains, prompting manufacturers to revisit sourcing strategies and to accelerate qualification of alternative suppliers in geographically diversified locations.

Beyond direct input costs, tariffs have also influenced logistics and inventory practices. Firms have responded by increasing buffer inventories, qualifying additional contract manufacturing organizations, and accelerating onshoring initiatives for critical processes where feasible. These responses mitigate immediate supply risk but introduce working capital implications and may shift lead times for product availability. Payers and providers are observing these operational adjustments and are increasingly attentive to unit cost trends and procurement predictability, which influences negotiation dynamics and formulary decisions.

In response, industry actors are prioritizing tariff impact assessments within commercial planning, embedding sensitivity analyses into pricing and contracting scenarios, and enhancing traceability across multi-tier supply networks. Policy engagement and coalition-building with trade and industry associations are also being used to communicate clinical and supply implications to policymakers. While tariffs have not altered the fundamental clinical value propositions of novel therapies, they have amplified the importance of supply chain agility, transparent cost drivers, and coordinated payer-provider-manufacturer dialogue to preserve patient access and treatment continuity.

Deeply granular segmentation perspectives across therapeutic classes indications routes of administration distribution channels and end user settings that guide tactical prioritization

Segmentation insights reveal nuanced implications across therapeutic class, indication, route of administration, distribution channel, and end user that are essential for prioritizing development and commercial resources. Based on therapeutic class, the landscape spans chemotherapy, immunotherapy, stem cell transplant, and targeted therapy, each with distinct clinical value propositions and operational demands; chemotherapy remains a cornerstone for some indications but faces increasing competition from immunotherapies and targeted agents that offer improved tolerability or durable remission in select populations. Based on indication, the portfolio covers leukemia, lymphoma, multiple myeloma, and myelodysplastic syndromes, with leukemia further defined into acute lymphoblastic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, and chronic myeloid leukemia, and lymphoma split into Hodgkin lymphoma and non-Hodgkin lymphoma, while multiple myeloma is examined across first line, second line, and third line and later settings; these granulated indications dictate trial design, regulatory endpoints, and sequencing strategies, with certain subtypes presenting clearer paths for targeted or cell-based interventions.

Based on route of administration, therapies delivered intravenously, orally, or subcutaneously present distinct adherence, monitoring, and outpatient care considerations that influence patient support programs and reimbursement mechanisms. Based on distribution channel, hospital pharmacies, online pharmacies, and retail pharmacies create differentiated logistics, dispensing, and prior authorization workflows that affect time-to-treatment and patient experience. Based on end user, clinics, home care, and hospitals represent divergent care settings where administration complexity, supportive-care needs, and reimbursement rules vary; home care expansion for oral and subcutaneous agents has meaningful implications for patient convenience and adherence programs, whereas complex cellular therapies necessitate coordination across specialized centers and transplant units. Integrating these segmentation lenses enables more precise commercial targeting, optimized trial recruitment strategies, and pragmatic planning for manufacturing scale and distribution complexity.

Tailored regional strategies and regulatory pathways across the Americas Europe Middle East Africa and Asia Pacific that determine access commercialization and clinical trial approaches

Regional dynamics materially influence clinical development pathways, regulatory approaches, and commercialization strategies, and three macro-regions warrant focused consideration. In the Americas, a combination of advanced clinical trial infrastructure, established payer systems, and strong venture and biopharma investment continues to drive rapid adoption of innovative therapies; reimbursement negotiations and health technology assessments are central to commercialization timelines, and U.S. regulatory mechanisms and specialty pharmacy networks set influential precedents for pricing and access agreements. Europe, Middle East & Africa presents a heterogeneous environment where centralized regulatory pathways coexist with diverse national reimbursement frameworks; access is often mediated by health technology appraisal processes and risk-sharing agreements, and regional supply chain hubs and clinical research networks offer opportunities for pan-regional trials and manufacturing collaboration. Asia-Pacific is characterized by a rapidly expanding patient population, growing domestic biopharma capabilities, and increasing regulatory harmonization in some markets, which together create significant opportunities for enrollment in clinical programs and for regional manufacturing scale-up, while payer constraints and price sensitivity in select countries require tailored access strategies and tiered pricing approaches.

Understanding these regional contours supports differentiated go-to-market plans, regulatory sequencing, and partnership models that account for country-level manufacturing capacity, reimbursement complexity, and patient access pathways. Cross-regional learning-such as leveraging real-world evidence generated in one jurisdiction to support value arguments elsewhere-can accelerate access when deployed thoughtfully and in alignment with local regulatory and payer expectations.

Corporate strategies and operational plays that combine scientific leadership partnerships and manufacturing agility to translate therapeutic innovation into clinical adoption

Company-level dynamics in the blood cancer therapeutics domain are increasingly shaped by strategic portfolio diversification, collaborative development models, and investments in specialized manufacturing and evidence generation. Leading developers are blending late-stage clinical programs in cellular and targeted therapies with earlier-stage assets that address unmet needs in refractory or molecularly defined subpopulations. Partnerships between biologics developers, diagnostics companies, and contract manufacturers are becoming standard to accelerate time to clinic and to ensure alignment between companion diagnostics and therapeutic launch plans.

Commercial strategies emphasize differentiated patient support offerings, including enhanced adherence programs for orally administered agents and integrated care coordination for cell therapies requiring multidisciplinary centers. Firms are also prioritizing post-approval evidence programs to address payer demands for real-world effectiveness and health economic outcomes. On the operational side, investments in flexible manufacturing capacity and multi-source supply chains are being used to hedge against geopolitical and tariff-driven risks. Corporate development activity reflects a preference for bolt-on acquisitions that provide either platform technologies, niche pipeline assets, or capacity for biologics and cell therapy production. Overall, successful companies combine scientific leadership with disciplined execution across regulatory interactions, payer engagement, and supply chain orchestration to translate clinical promise into sustainable patient access.

Practical strategic imperatives for leaders to align development evidence supply resilience and patient-centered access to accelerate adoption and manage policy risk

Industry leaders should adopt a set of prioritized, actionable measures to navigate the evolving clinical, commercial, and policy landscape for blood cancer therapeutics. First, align early development with evidence pathways that address both regulatory approval and payer value frameworks, embedding real-world endpoints and health economic measures into pivotal and post-approval programs. Second, diversify sourcing and invest in flexible manufacturing capabilities while accelerating qualification of alternate suppliers and regional contract manufacturers to reduce tariff and logistics exposure. Third, design patient-centric access models that reflect route-of-administration differences and support home-care delivery where clinically appropriate, enabling broader uptake while managing total cost of care implications.

Fourth, pursue strategic collaborations that integrate diagnostics, therapeutics, and data platforms to enable precise patient selection and to strengthen value propositions. Fifth, engage proactively with payers and policymakers through transparent evidence-sharing and pilot agreements that demonstrate impact on clinically meaningful outcomes and system-level efficiencies. Sixth, prioritize commercial capabilities that support complex product launches, including specialty pharmacy partnerships, digital adherence tools, and robust hub services for multi-step therapies. Finally, institutionalize scenario planning and sensitivity analyses for macroeconomic and trade policy variables to ensure rapid adaptation when external conditions shift. Collectively, these recommendations create a resilient framework for translating innovation into sustained patient access and commercial viability.

A rigorous mixed methods approach combining stakeholder interviews regulatory data and supply chain analysis to produce evidence triangulated insights and documented assumptions

The research methodology underpinning this executive summary integrates multi-source evidence and stakeholder input to ensure robust, actionable conclusions. Primary evidence collection included structured interviews with clinical investigators, commercial leaders, manufacturing specialists, and payer representatives to capture contemporary practice patterns, operational constraints, and reimbursement considerations. Secondary analysis drew on regulatory approvals, clinical trial registries, published peer-reviewed literature, and public health guidance to map therapeutic modalities, trial endpoints, and safety profiles in a reproducible manner.

Supply chain and tariff impact assessments used import/export data, contract manufacturing mappings, and logistics performance indicators to evaluate sourcing risk and lead-time vulnerabilities. The approach emphasized triangulation-cross-validating findings across primary interviews, regulatory documents, and operational datasets-to reduce bias and enhance confidence in conclusions. Analytical limitations were addressed by transparently documenting assumptions, distinguishing empirical observations from expert opinion, and noting areas where emerging data could shift interpretations. Quality assurance processes included peer review by subject matter experts and consistency checks across segmentation and regional analyses to ensure coherence and practical relevance for decision-makers.

Synthesis and forward-looking perspective emphasizing integrated operational evidence and access strategies to convert innovation into timely patient benefit

In conclusion, the blood cancer therapeutics field is at an inflection point where clinical innovation, diagnostic precision, and evolving payer expectations intersect to create both opportunity and complexity. The success of novel agents will depend as much on demonstrable patient benefit as on the ability to deliver therapies reliably, to generate meaningful real-world evidence, and to design reimbursement approaches that reflect long-term value. Supply chain pressures and trade policy dynamics have highlighted the importance of operational resilience as an integral component of commercial readiness.

Decision-makers should therefore adopt integrated strategies that align scientific prioritization with manufacturability, payer engagement, and patient-centric delivery models. Those who proactively address evidence requirements, diversify supply options, and build flexible commercial capabilities will be best positioned to convert scientific advances into durable improvements in patient outcomes while maintaining financial and operational sustainability. The path forward requires collaboration across developers, clinicians, payers, and policymakers to ensure that therapeutic innovation translates into equitable and timely access for patients living with hematologic malignancies.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of next-generation CAR T-cell therapies addressing relapse in refractory blood cancer patients
  • 5.2. Rising investment in bispecific antibody platforms for targeted dual antigen engagement in leukemias
  • 5.3. Integration of minimal residual disease monitoring with digital biomarkers to personalize treatment regimens
  • 5.4. Advancements in oral BTK inhibitors improving patient adherence and reducing infusion center dependency
  • 5.5. Emergence of biosimilar rituximab alternatives driving cost competition and wider therapy access
  • 5.6. Clinical evaluation of epigenetic modulators targeting histone methyltransferases in multiple myeloma
  • 5.7. Pipeline progression of antibody-drug conjugates with novel linkers for enhanced selectivity in lymphoma

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Blood Cancer Drugs Market, by Therapeutic Class

  • 8.1. Chemotherapy
  • 8.2. Immunotherapy
  • 8.3. Stem Cell Transplant
  • 8.4. Targeted Therapy

9. Blood Cancer Drugs Market, by Indication

  • 9.1. Leukemia
    • 9.1.1. Acute Lymphoblastic Leukemia
    • 9.1.2. Acute Myeloid Leukemia
    • 9.1.3. Chronic Lymphocytic Leukemia
    • 9.1.4. Chronic Myeloid Leukemia
  • 9.2. Lymphoma
    • 9.2.1. Hodgkin Lymphoma
    • 9.2.2. Non-Hodgkin Lymphoma
  • 9.3. Multiple Myeloma
    • 9.3.1. First Line
    • 9.3.2. Second Line
    • 9.3.3. Third Line And Later
  • 9.4. Myelodysplastic Syndromes

10. Blood Cancer Drugs Market, by Route Of Administration

  • 10.1. Intravenous
  • 10.2. Oral
  • 10.3. Subcutaneous

11. Blood Cancer Drugs Market, by Distribution Channel

  • 11.1. Hospital Pharmacies
  • 11.2. Online Pharmacies
  • 11.3. Retail Pharmacies

12. Blood Cancer Drugs Market, by End User

  • 12.1. Clinics
  • 12.2. Home Care
  • 12.3. Hospitals

13. Blood Cancer Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Blood Cancer Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Blood Cancer Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Bristol-Myers Squibb Company
    • 16.3.2. AbbVie Inc.
    • 16.3.3. Roche Holding AG
    • 16.3.4. Johnson & Johnson
    • 16.3.5. Takeda Pharmaceutical Company Limited
    • 16.3.6. Amgen Inc.
    • 16.3.7. Novartis AG
    • 16.3.8. AstraZeneca plc
    • 16.3.9. Gilead Sciences, Inc.
    • 16.3.10. Sanofi S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. BLOOD CANCER DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. BLOOD CANCER DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. BLOOD CANCER DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHEMOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY IMMUNOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY STEM CELL TRANSPLANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY TARGETED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CHRONIC MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY NON-HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY THIRD LINE AND LATER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY MYELODYSPLASTIC SYNDROMES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 269. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 272. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 273. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 274. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 287. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 288. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 289. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 290. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 291. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 292. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 293. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 294. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 305. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2018-2024 (USD MILLION)
  • TABLE 308. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY THERAPEUTIC CLASS, 2025-2032 (USD MILLION)
  • TABLE 309. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 311. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
  • TABLE 312. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
  • TABLE 313. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2018-2024 (USD MILLION)
  • TABLE 314. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY LYMPHOMA, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY MULTIPLE MYELOMA, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC BLOOD CANCER DRUGS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 323. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 324. GLOBAL BLOOD CANCER DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 325. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 326. ASEAN BLOOD CANCER DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 327. ASEAN BLOOD CA